Trainees complete a series of professional development workshops, six for PhD students and three for MSc students, offered through MITACS and partner institutions, including Université Laval’s Service de développement professionnel and entrepreneurship programs at Université Laval and UBC. Training covers effective communication, leadership, networking, project and time management, R&D coordination, scientific writing and presentation, and career planning. With support from ICARE-Nanomed’s academic-industry liaison committee, trainees also receive preparation for industrial placements, including guidance on interviews, résumé development, scholarship applications, scientific writing, and inclusive research practices.

Trainees put these skills into practice through interdisciplinary and cross-institutional collaborations in both academic and industrial environments. Dedicated workshops emphasize the clear communication and documentation of analytical methodologies to support reproducibility across partner laboratories. Experimental results are peer-evaluated and cross-validated under the guidance of an expert in nanoparticle metrology at the National Research Council. During mobility placements and Annual Research Days, trainees present their research and discuss the translational challenges and opportunities associated with their technologies, strengthening their ability to communicate experimental design, methods, and findings with clarity and precision. Each graduate student also mentors at least one undergraduate student, providing practical experience in supervision, knowledge transfer, and leadership.

Webinars and Annual Research Days introduce trainees to topics that are essential to nanomedicine development but are rarely covered comprehensively in traditional natural sciences and engineering programs. These include nanotoxicology, safety and efficacy testing, in vitro pharmacology, Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP), Good Distribution Practice (GDP), Quality Control, Quality by Design (QbD), regulatory review, clinical trial design, and new drug applications. During industrial placements, trainees gain additional exposure to bioactivity, pharmacokinetics, toxicity, adverse-event monitoring, validation testing, and manufacturing processes, learning how analytical data inform the preclinical development of nanoparticle-based therapeutics. Industry experts provide training on ISO standards and risk-management frameworks relevant to nanomedicines, while Health Canada representatives engage with trainees annually to discuss regulatory approval pathways in Canada and other jurisdictions.

Trainees learn to use analytical cascade assays not only to evaluate nanoparticle formulation, stability, and biological interactions, but also to build robust bodies of scientific evidence that can reveal novel phenomena and support the development of new nanomedicine products. Webinars and workshops on intellectual property and entrepreneurship introduce trainees to patent fundamentals, patent searching, application components, IP risk management, and strategies for protecting and translating research discoveries. Training is delivered by co-investigators with experience in nanomedicine translation, together with industry leaders and representatives from the National Research Council, helping trainees recognize promising innovations and understand the pathway from scientific discovery to potential application.